Fructose-1,6-bisphosphatase as a therapeutic target for type 2 diabetes: from molecular mechanisms to clinical translation
{{output}}
Type 2 diabetes mellitus (T2DM) affects over 415 million individuals globally, with excessive hepatic glucose production representing a primary contributor to hyperglycaemia. Fructose-1,6-bisphosphatase (FBP1), a rate-limiting gluconeogenic enzyme, has emerged... ...
